<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201210049672N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-19</date_registration>
      <primary_sponsor>Vice-Chancellery for Research Hormozgan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of different doses of ketamine and propofol for changing the dressing in burn patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of different doses of ketamine and propofol for sedation and analgesia for changing the dressing in burn patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62522</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: Simple randomization with individuals as units of randomization along with allocation concealment: 120 unclear envelopes and 120 cards with the names of the groups (A, B) will be prepared (60 cards for each group). The cards will be put into the envelopes and the envelopes will be sealed and provided to the investigator. Upon entrance of each patient to the study, the envelopes will be shuffled and one will randomly be selected. The patient will be allocated to group A or B  based on the card inside the selected envelope, Blinding description: The solutions will be prepared for injection in advance by an individual not involved in the study and they will only have labels indicating the groups of the study; therefore, the patients, the investigator, the care giver, and the outcome assessor will be unaware of the injected drugs.</study_design>
      <phase>3</phase>
      <hc_freetext>Second- and third-degree burns.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: First the patient will receive 1-2 mg intravenous ketamin (MFR:Sterop Co., Belgium) for induction (Each ampule contains 500 mg ketamin/10 ml; therefore, each ml contains 50 mg ketamine, which will be diluted with 4 ml distilled water). During the procedure, whenever the patient's pain score is &gt;3 based on his/her facial expression, 1-3 ml propofol 1% will be injected (each ampule contains 200 mg propofol 1%/20 ml, DoNcKood.phar Co. Korea) in divided intravenous doses (taking 30-100 μ/kg/min as reference based on the interval between injections and the patient's weight). Intervention 2: Intervention group: Ketamine will be diluted with distilled water so that each 1 ml contains 10 mg ketamine (Each ampule contains 500 mg ketamin/10 ml; therefore, each ml contains 50 mg ketamine, which will be diluted with 4 ml distilled water). Then, equal proportions of ketamine and propofol 1% (each ampule contains 200 mg propofol 1%/20 ml) will be mixed in a 10-ml syringe so that each ml of this 0.5% ketofol 0.5% mixture contains 5 mg ketamine and 5 mg propofol. Then, first 0.5-1 mg/kg of the mixture will be injected intravenously for induction. During the procedure, whenever the patient's pain score is &gt;3, 0.1-0.5 mg/kg of the same mixture will be injected.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bibimona Razavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jomhouri Eslami Blvd., Payambar Azam Hospital</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9791991551</zip>
        <telephone>+98 76 3334 5009</telephone>
        <email>bibimonarazavi.hums@gmail.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bibimona Razavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jomhouri Eslami Blvd., Payambar Azam Hospital</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>979199155</zip>
        <telephone>+98 76 3334 5009</telephone>
        <email>bibimonarazavi.hums@gmail.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 15-65 years
Second- and third-degree burns
Burn area of 10-70%
Daily dressing change before skin graft in the operating room with American Society of Anesthesiologists (ASA) class 1-3
Ability to speak and perceive the Persian language</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Drug addiction
Respiratory and cardiac diseases
Renal disorders
Hypersensitivity to analgesic drugs, ketamine, and propofol
History of psychiatric disorders
History of seizure
American Society of Anesthesiologists (ASA) class &gt;3</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z48.00</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for change or removal of nonsurgical wound dressing</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: First the patient will receive 1-2 mg intravenous ketamin (MFR:Sterop Co., Belgium) for induction (Each ampule contains 500 mg ketamin/10 ml; therefore, each ml contains 50 mg ketamine, which will be diluted with 4 ml distilled water). During the procedure, whenever the patient's pain score is &gt;3 based on his/her facial expression, 1-3 ml propofol 1% will be injected (each ampule contains 200 mg propofol 1%/20 ml, DoNcKood.phar Co. Korea) in divided intravenous doses (taking 30-100 μ/kg/min as reference based on the interval between injections and the patient's weight).</i_keyword>
      <i_keyword>Intervention group: Ketamine will be diluted with distilled water so that each 1 ml contains 10 mg ketamine (Each ampule contains 500 mg ketamin/10 ml; therefore, each ml contains 50 mg ketamine, which will be diluted with 4 ml distilled water). Then, equal proportions of ketamine and propofol 1% (each ampule contains 200 mg propofol 1%/20 ml) will be mixed in a 10-ml syringe so that each ml of this 0.5% ketofol 0.5% mixture contains 5 mg ketamine and 5 mg propofol. Then, first 0.5-1 mg/kg of the mixture will be injected intravenously for induction. During the procedure, whenever the patient's pain score is &gt;3, 0.1-0.5 mg/kg of the same mixture will be injected.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: At the end of the procedure. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sedation. Timepoint: At the end of the procedure. Method of measurement: Ramsay Sedation Scale.</sec_outcome>
      <sec_outcome>Patient satisfaction. Timepoint: At the end of the procedure. Method of measurement: Poor/moderate/good/excellent.</sec_outcome>
      <sec_outcome>Surgeon satisfaction. Timepoint: At the end of the procedure. Method of measurement: Poor/moderate/good/excellent.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice-Chancellery for Research Hormozgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-12</approval_date>
        <contact_name>Ethics Committee of Hormozgan University of Medical Sciences</contact_name>
        <contact_address>Imam Hossein Blvd., across from Kargaran Sports Complex, Faculty of Medicine Bandar Abbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
